Impact of overweight, obesity, and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors.

Authors

Antonio Di Meglio

Antonio Di Meglio

Institut Gustave Roussy, Villejuif, France

Antonio Di Meglio , Gwenn Menvielle , Agnes Dumas , Arnauld S. Gbenou , Thomas Bovagnet , Elise Martin , Arlindo R. Ferreira , Laurence Vanlemmens , Olivier Arsene , Mahmoud Ibrahim , Johanna Wassermann , Anne-Laure Martin , Jerome Lemonnier , Lucia Del Mastro , Lee Jones , Ann H. Partridge , Jennifer A. Ligibel , Fabrice Andre , Stefan Michiels , Ines Maria Vaz Duarte Luis

Organizations

Institut Gustave Roussy, Villejuif, France, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, Centre Oscar Lambret, Lille, France, Centre Hospitalier de Blois, Blois, France, Centre Hospitalier Régional d'Orléans, Orléans, France, Pitié-Salpêtrière Hospital, Sorbonne University, Cancer University Institute, Paris, France, Unicancer, Paris, France, Department of Medical Oncology, IRCCS AOU San Martino–IST, National Cancer Institute, Genova, Italy, Memorial Sloan Kettering Cancer Center, New York, NY, Dana-Farber Cancer Institute, Boston, MA

Research Funding

Other Government Agency
Other Foundation, Susan G. Komen for the cure Career Catalyst Research Grant (CCR17483507) to Ines Vaz-Luis; European Society for Medical Oncology (ESMO) Clinical Research Fellowship to Antonio Di Meglio

Background: Overweight and obesity are strongly linked to poorer BC-specific outcomes, quality of life and financial burden in cancer care. Weight loss interventions have the potential to improve such outcomes. Fewer data exist on whether excess weight and post-diagnosis weight changes impact the ability of BC survivors to return to work (RTW). Methods: CANTO (NCT01993498) is a multicenter prospective longitudinal study of 12000 patients (pts) with stage I-III BC that characterizes long-term toxicities of BC treatment. Of 5801 pts enrolled from 2012-2014 (last data lock), we identified 1874 pts who were professionally active at BC diagnosis, ≥5 years (yrs) younger than minimum legal retirement age (62 yrs) and with updated work status 2 yrs after diagnosis. Logistic regression models evaluated the impact of body mass index (BMI) at diagnosis and of weight changes over 2 yrs after diagnosis on odds of non-RTW, adjusting for age, education, income, BC treatment and recreational physical activity (PA). Results: 37% pts were overweight or obese at diagnosis (BMI ≥25 kg/m2): 34% of them gained ≥5% and 16% lost ≥5% weight after diagnosis. Rates of non-RTW at 2 yrs were significantly higher in overweight or obese vs under or normal weight pts (27% vs 18%, p≤.001; adjusted odds ratio 1.37, 95% Confidence Interval [CI] 1.04-1.80, p = .017). Overweight and obese pts who did not RTW experienced higher increments in weight (mean [95% CI]: +3.6% [+2.3, +4.9] vs +1.5% [+0.8, +2.2]) and reported more modest changes in PA (mean [95% CI]: +1.0 [-1.4, +3.5] vs +2.1 [+0.8, +3.3] MET-h/week) vs those who did RTW. Weight changes independently impacted odds of non-RTW in overweight and obese pts (p for interaction weight change*BMI ≤.001): a 5% weight gain was associated with 17% increase in adjusted odds of non-RTW (95% CI 2-35%, p = .024), whereas a loss ≥5% with 60% reduced odds of non-RTW vs weight gain (95% CI 18-82%, p = .013). Conclusions: Excess weight and weight changes are significantly associated with occupational reintegration after BC in overweight and obese pts. Randomized studies testing dedicated weight control interventions should also measure outcomes of social rehabilitation in this large subset of survivors. Clinical trial information: NCT01993498

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Late and Long-Term Adverse Effects

Clinical Trial Registration Number

NCT01993498

Citation

J Clin Oncol 37, 2019 (suppl; abstr 11562)

DOI

10.1200/JCO.2019.37.15_suppl.11562

Abstract #

11562

Poster Bd #

254

Abstract Disclosures

Similar Abstracts

First Author: Po-Hua Chen

First Author: Keenan B. Caddell

Abstract

2023 ASCO Quality Care Symposium

Demand for oncology visits among low-risk breast cancer survivors.

First Author: Emily H. Douglas